Abstract: A classifying device that classifies aggregates and includes: a plurality of metallic porous membranes respectively including: a membrane section including a first principal surface, a second principal surface, and a plurality of through-holes. Among each of the plurality of metallic porous membranes, the through-holes have mutually different dimensions, and some of the plurality of through-holes in at least a first of the plurality of metallic porous membranes are configured to have different dimensions sufficient to release pressure applied to the first of the plurality of metallic porous membranes without degrading classification accuracy of the first of the plurality of metallic porous membranes. The plurality of metallic porous membranes are arranged in series from an upstream side of a flow path through which a liquid containing the aggregates flows in a descending order of the different dimensions of the through-holes of the plurality of metallic porous membranes.

Abstract: An image processing method is configured to input a test image to a first learning model, input an output image to a second learning model and output an output image as a result image in which the position of the detected part is indicated by a representative point. The first learning model is constructed by deep learning using teacher data associating a first image in which a marker is expressed and a second image in which the marker is not expressed. The first and the second images are captured to include a same cell. The second learning model is constructed by deep learning using teacher data associating a third image, which is captured to include a cell and in which the marker is expressed, and information representing a position of the representative point included in the third image.

Abstract: An image processing method is configured to input a test image to a first learning model, input an output image to a second learning model and output an output image as a result image in which the position of the detected part is indicated by a representative point. The first learning model is constructed by deep learning using teacher data associating a first image in which a marker is expressed and a second image in which the marker is not expressed. The first and the second images are captured to include a same cell. The second learning model is constructed by deep learning using teacher data associating a third image, which is captured to include a cell and in which the marker is expressed, and information representing a position of the representative point included in the third image.

Abstract: A metallic porous membrane that classifies cell aggregates includes a membrane section having a first principal surface for capturing the cell aggregates, a second principal surface opposing the first principal surface, and a plurality of through-holes communicating with the first principal surface and the second principal surface.

Abstract: A metallic porous membrane that classifies cell aggregates includes a membrane section having a first principal surface for capturing the cell aggregates, a second principal surface opposing the first principal surface, and a plurality of through-holes communicating with the first principal surface and the second principal surface.

Abstract: A metallic porous membrane that classifies cell aggregates includes a membrane section having a first principal surface for capturing the cell aggregates, a second principal surface opposing the first principal surface, and a plurality of through-holes communicating with the first principal surface and the second principal surface.

Abstract: Provided is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: [in the formula, R1 to R5, A, and *1 to *3 are as defined in Description].

Abstract: Provided is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: [in the formula, R1 to R5, A, and *1 to *3 are as defined in Description].

Abstract: E2F-inhibiting compounds are represented by the general formula: R1-A-R2 wherein A represents a peptide sequence comprising a partial amino acid sequence having at least 12 continuous residues in the sequence of the dimerization region or DNA binding region of the E2F family), which are useful as a therapeutic agent of diseases such as tumor and arteriosclerosis, for which abnormal cellular growth is responsible.

Abstract: There is provided an indole derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of malignant tumor or a brain neurodegenerative disease: (wherein C ring represents a benzene ring or a cyclohexene ring; X and Y are the same or different and each represent —CH2—, —CH(OH)—, —CH(ORx)—, —CH(SRY)— or carbonyl; R1 and R2 are the same or different and each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or substituted or unsubstituted lower alkanoyl or R1 and R2 form a benzene ring together two carbon atoms each being adjacent thereto; and R3, R4 and R5 are the same or different and each represent a hydrogen atom, substituted or unsubstituted lower alkyl, etc.

Abstract: UCS 1025 derivatives having antitumor activity or antibacterial activity which are represented by formula (I): wherein R1 represents hydrogen, lower alkyl, etc.; R2 represents hydrogen, or is combined with R3 to represent a bond, etc., or is combined with R4 to represent —O(C?O)—, etc.; R3 represents hydrogen, etc., or is combined with R2 to represent a bond, etc.; R4 represents hydrogen, etc., or is combined with R2 to represent —(C?O)O—, etc.; R5 represents hydrogen or is combined with R6 to represent a bond; R6 represents hydrogen, etc., or is combined with R5 to represent a bond; R7 represents hydrogen or is combined with R8 to represent ?O; R8 represents hydroxy or is combined with R7 to represent ?O; ---- represents a single bond or a double bond, and a represents a single bond (two carbon atoms to which a is bound are combined to form a single bond) or an oxygen atom, or pharmaceutically acceptable salts thereof.

Abstract: E2F-inhibiting compounds are represented by the formula: R1—A—R2 wherein A represents a peptide sequence comprising a partial amino acid sequence having at least 12 continuous residues in the sequence of the dimerization region or DNA binding region of the E2F family, which are useful as a therapeutic agent of diseases such as tumor and arteriosclerosis, for which abnormal cellular growth is implicated.

Abstract: A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof:

Abstract: A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof: Ar1—S—R1—S—Ar2 wherein R1 represents a nonmetal bridging group; Ar1 and Ar2 independently represent a group selected from the group consisting of an aryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group and said aryl group may have one to three substituents other than hydroxyl group on its ring; and a heteroaryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group, and said heteroaryl group may have one to three substituents other than hydroxyl group on its ring.

Abstract: A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof:

Abstract: The present invention relates to radicicol derivatives represented by the following formula (I) or pharmacologically acceptable salts thereof: ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represents hydrogen, alkanoyl, alkenoyl or tert-butyldimethylsilyl; (1) when X represents halogen, Y represents an oxygen atom or R.sup.4 --O--N (wherein R.sup.4 represents hydrogen or substituted or unsubstituted lower alkyl); and R.sup.3 represents hydrogen, alkanoyl, alkenoyl or the like; and (2) when X and R.sup.3 are combined with each other to represent a single bond; Y represents R.sup.4B --O--N (wherein R.sup.4B has the same meaning as R.sup.4). The radicicol derivatives of the present invention demonstrate tyrosine kinase inhibition activity and pharmacological activities such as antitumor, antimicrobial or immunosuppression effects.

Abstract: The present invention relates to UCT1072 compounds represented by formula (I): wherein R.sup.1 and R.sup.2 together represent --CH(OH)CH.sub.2 O-- or --CH.sub.2 CH.sub.2 CH(OH)CH.sub.2 --.

Abstract: The present invention relates to chrolactomycin compound represented by the following formula (I): ##STR1## or pharmaceutically acceptable salts thereof having antibacterial and antitumor activities.

Abstract: The present invention relates to a farnesyltransferase inhibitor and an antitumor agent comprising, as an active ingredient, a piperazinedione derivative represented by formula (I): ##STR1## wherein R.sup.1 and R.sup.2 independently represent lower alkyl, lower alkoxyalkyl, substituted or unsubstituted aryl, or aralkyl; R.sup.3 and R.sup.4 independently represent mercapto, lower alkanoylthio, aroylthio, lower alkoxycarbonylthio, or aryloxycarbonylthio, or alternatively R.sup.3 and R.sup.4 are combined together to form disulfide; and R.sup.5 and R.sup.6 independently represent hydrogen, lower alkyl, lower alkoxyalkyl, hydroxyalkyl, lower alkanoyloxyalkyl, aroyloxyalkyl, aralkyloxyalkyl, or aralkyl.

Abstract: UCS1025 compounds represented by the following formula (I): ##STR1## wherein R represents hydrogen or hydroxyl group, or tautomers or pharmacologically acceptable salts thereof.